Information Provided By:
Fly News Breaks for July 17, 2018
BCRX
Jul 17, 2018 | 07:34 EDT
As previously reported, BofA/Merrill upgraded BioCryst to Neutral from Underperform and raised its price target to $7 from $4. Analyst Tazeen Ahmad believes proof of concept data from the Zenith trial for acute treatment of hereditary angloedema, or HAE, could be a leading indicator of future success of Phase 3 data in chronic HAE in 2019. The analyst also increased his estimates for recently launched drugs saying they could help increase the addressable treatable population.
News For BCRX From the Last 2 Days
There are no results for your query BCRX